Research graph
References from Isavuconazole and Micafungin Elicit Synergistic Antifungal and Immunomodulatory Activity Against Azole-Resistant <i>Aspergillus fumigatus</i>. Local targets link to admitted publications; unresolved targets remain external evidence.
Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management
10.1016/j.cmi.2018.11.027 · 2019 · External reference
Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients
10.1093/jac/dkz258 · 2019 · External reference
Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs
10.1093/jac/dkx354 · 2018 · External reference
In vitro combination of isavuconazole with echinocandins against azole-susceptible and -resistant Aspergillus spp
10.1128/aac.01382-17 · 2017 · External reference
In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates
10.1093/jac/dkaa185 · 2020 · External reference
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae
10.1086/589305 · 2008 · External reference
Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure
10.1086/589304 · 2008 · External reference
Immunocompromised hosts: immunopharmacology of modern antifungals
10.1086/589290 · 2008 · External reference
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics
10.1093/jac/dkae415 · 2025 · External reference
Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus
10.1038/s41467-018-05497-7 · 2018 · External reference
Antifungal drugs influence neutrophil effector functions
10.1128/aac.02409-18 · 2019 · External reference
Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases
10.1093/jac/dky463 · 2019 · External reference
Analysis of growth characteristics of filamentous fungi in different nutrient media
10.1128/jcm.39.2.478-484.2001 · 2001 · External reference
An overview of isavuconazole clinical use: a multicentre analysis of indications, exposure and hepatic safety
10.1007/s40261-025-01432-z · 2025 · External reference
Treatment of invasive pulmonary aspergillosis and preventive and empirical therapy for invasive candidiasis in adult pulmonary and critical care patients: an Official American Thoracic Society Clinical Practice Guideline
10.1164/rccm.202410-2045st · 2025 · External reference
